Replies to post #31525 on Rebus Holdings Inc (RBSH)

[KOmani]

Wait.

They applied for the patent on Friday?

Someone wake up Hdog.

[Jama87]

“For future trials, companies may need a metric ton per year of thapsigargin, Christensen says.” From 2017 https://pubs.acs.org/doi/10.1021/cen-09519-notw4

So based on the above quote larger scale manufacturing may need to come before a phase 3 trial starts. I mean they need the drug to supply to a large volume of patients. If they are scaling up capacity to make this drug then perhaps a phase 3 Is on the horizon. It’s promising that they are partnered with Phyton to produce it. It seems like the Phyton partnership may be paving the way for the phase 3 of mipsagargin.

[Jama87]

This timing makes me think phase 3 is coming

My understanding of these events:

Mipsagargin already had a successful phase 2 for hepatic cancer (https://pubmed.ncbi.nlm.nih.gov/31212948/) but It is speculated that they can’t start bigger trials until they can manufacture more due to limited availability of thapsigargin. (https://pubs.acs.org/doi/10.1021/cen-09519-notw4)

Their partner Phyton can make the difficult to produce chemical. (https://phytonbiotech.com/phyton-biotech-achieves-manufacturing-milestone-with-thapsigargin-the-active-agent-in-mipsagargin/j

Now that manufacturing capacity is ready there is a potential suspected reverse merger so they can capitalize on the value of having a phase 3 drug and being publicly traded. At the same time as patent submission by Phyton?

This is all just speculation on my part but very interesting timing.